

2479

Dr D Walford

FVIII CONCENTRATE WITH REDUCED HEPATITIS RISK

Although we have had discussions with Travenol about their product, we have so far had no application of any kind for a reduced hepatitis risk FVIII. It is our understanding that Travenol propose to apply for a CTX some time around March 1983. This, however, is pre-empted by Immuno's recent meeting with the haemophilia centre directors and the directors of BPL and PFC, the outcome of which is, we are led to believe, a multi centre clinical trial of the product in named patients. I had not heard that Travenol proposed to hold a symposium, although it would be very much in character were they to do so. The Immuno meeting is said to have been quite an expensive exercise at Heathrow. I was not invited, but my information comes indirectly via John Holgate from one of the participants. We also hear that overseas experts from Travenol have had a meeting with Duncan Thomas and his people at NIBSC and furthermore that there may be other companies interested in this field apart from those who have already made or hope to make hepatitis-free FVIII biosynthetically. It is possible that Richard Lane may be able to give you more information on this subject.

GRO-C

DR L K FOWLER
MB4
Rm 1619 MT
Ext 3129

31 December 1982

cc

Dr J A Holgate

Mr Godfrey *Mr Godfrey*